Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 21

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Dermatitis atopic

Not recruiting

A study testing TRIV-509 compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:WBP2721
  • Sponsor:Triveni Bio Inc.

Pneumonia+1

Not recruiting

A study testing trimodulin in hospitalized adult patients with community-acquired pneumonia including COVID-19 pneumonia

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Dermatomyositis

Not recruiting

A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

A Study of XC001 Gene Therapy with Bypass Surgery for Patients with Coronary Artery Disease and Weakened Heart Function at Risk for Incomplete Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Xylocor Therapeutics Inc.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 1815368
  • Sponsor:Boehringer Ingelheim International GmbH

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.